Patent Results
Insulin Glargine/lixisenatide Fixed Ratio Formulation
- Published: Apr 24, 2018
- Filed: Dec 10, 2015
- Earliest Priority: Dec 12 2014
- Family: 22
- Cited Works: 939
- Cited by: 0
- Cites: 514
- Sequences: 2
- Additional Info: Cited Works Full text Published Sequence
- Owner: Sanofi-aventis Deutschland Gmbh, Saudi Arabian Oil Company
- Applicant: Sanofi Aventis Deutschland
Pharmaceutical Composition For Use In The Treatment Of A Neurodegenerative Disease
- Published: Jun 5, 2018
- Filed: May 4, 2016
- Earliest Priority: Sep 01 2011
- Family: 36
- Cited Works: 967
- Cited by: 0
- Cites: 507
- Sequences: 5
- Additional Info: Cited Works Full text Published Sequence
- Applicant: Sanofi Aventis Deutschland, Univ Ulster
Use Of Ave0010 For The Treatment Of Diabetes Mellitus Type 2
- Published: May 29, 2018
- Filed: Aug 15, 2016
- Earliest Priority: Aug 30 2010
- Family: 32
- Cited Works: 940
- Cited by: 0
- Cites: 520
- Sequences: 2
- Additional Info: Cited Works Full text Published Sequence
- Owner: Sanofi-aventis Deutschland Gmbh
- Applicant: Sanofi Aventis Deutschland
Pharmaceutical Combination For Improving Glycemic Control As Add-on Therapy To Basal Insulin
- Published: Nov 21, 2017
- Filed: May 9, 2012
- Earliest Priority: May 13 2011
- Family: 29
- Cited Works: 941
- Cited by: 2
- Cites: 510
- Sequences: 2
- Additional Info: Cited Works Full text Published Sequence
- Owner: Sanofi-aventis Deutschland Gmbh
- Applicant: Niemoeller Elisabeth, Silvestre Louise, Boka Gabor, Miossec Patrick, Sanofi Aventis Deutschland
Treatment Of Type 2 Diabetes Mellitus Patients
- Published: Dec 25, 2018
- Filed: Mar 17, 2016
- Earliest Priority: Mar 18 2015
- Family: 21
- Cited Works: 1036
- Cited by: 0
- Cites: 522
- Sequences: 2
- Additional Info: Cited Works Full text Published Sequence
- Owner: Sanofi-aventis Deutschland Gmbh
- Applicant: Sanofi Aventis Deutschland
Pharmaceutical Composition Comprising A Glp-1 Agonist And Methionine
- Published: Jul 18, 2017
- Filed: Nov 11, 2010
- Earliest Priority: Nov 13 2009
- Family: 54
- Cited Works: 849
- Cited by: 0
- Cites: 529
- Additional Info: Cited Works Full text Published
- Owner: Sanofi-aventis Deutschland Gmbh
- Applicant: Brunner-schwarz Anette, Mueller Werner, Siefke-henzler Verena, Sanofi Aventis Deutschland
Pharmaceutical Composition Comprising A Glp-1-agonist And Methionine
- Published: Jul 24, 2018
- Filed: May 15, 2017
- Earliest Priority: Nov 13 2009
- Family: 54
- Cited Works: 971
- Cited by: 0
- Cites: 520
- Sequences: 4
- Additional Info: Cited Works Full text Published Sequence
- Owner: Sanofi-aventis Deutschland Gmbh
- Applicant: Sanofi Aventis Deutschland
Pharmaceutical Composition Comprising A Glp-1 Agonist, An Insulin And Methionine
- Published: Jul 24, 2018
- Filed: Nov 11, 2010
- Earliest Priority: Nov 13 2009
- Family: 65
- Cited Works: 967
- Cited by: 0
- Cites: 504
- Additional Info: Cited Works Full text Published
- Owner: Sanofi-aventis Deutschland Gmbh
- Applicant: Hagendorf Annika, Hauck Gerrit, Mueller Werner, Schoettle Isabell, Siefke Henzler Verena, Tertsch Katrin, Sanofi Aventis Deutschland
High-purity Quinoline Derivative And Method For Manufacturing Same
- Published: Apr 16, 2019
- Filed: Aug 26, 2015
- Earliest Priority: Aug 28 2014
- Family: 19
- Cited Works: 2017
- Cited by: 0
- Cites: 497
- Additional Info: Cited Works Full text
- Owner: Eisai R&d Management Co. Ltd
- Applicant: Eisai R&d Man Co Ltd
High-purity Quinoline Derivative And Method For Manufacturing Same
- Published: Sep 10, 2019
- Filed: Dec 21, 2018
- Earliest Priority: Aug 28 2014
- Family: 19
- Cited Works: 2067
- Cited by: 0
- Cites: 515
- Additional Info: Cited Works Full text
- Owner: Eisai R&d Management Co. Ltd
- Applicant: Eisai R&d Man Co Ltd
{{::'analysis.preview.CITED_WORKS_ANALYSIS.title' | message}}
{{::'analysis.preview.view.full' | message}}
Add New Note
Sorry, you can't add a note to multiple items. You can add a note to your search as a saved query. Did you want to save this search and add a note to it?